Acrivon Therapeutics Inc. (ACRV) Live Share Price, Invest From India

Acrivon Therapeutics Inc. Stock Performance

as on June 19, 2026 at 2:16 pm IST

Day's Low
Day's High
$1.51
Day's Price Range
$1.61
$1.57
3.82%
Downside
2.55%
Upside
52 Week's Low
52 Week's High
$1.15
52-Week Price Range
$3.56
$1.57
26.75%
Downside
126.75%
Upside

Acrivon Therapeutics Inc. share price movements today

Previous Close: $1.52
Open: $1.54
Volume: 935.1K
Day's Low - High: $1.51 - $1.61
52 Week Low - High: $1.15 - $3.56

Acrivon Therapeutics Inc. Historical Returns

1 Month Return: -1.88 %
3 Month Return: -7.65 %
1 Year Return: + 26.61 %
3 Year Return: -87.44 %
5 Year Return: 0 %

Acrivon Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Acrivon Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$65.1M

EPS (TTM)

-2.0657

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-80.9M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-60.39%

Acrivon Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Acrivon Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Acrivon Therapeutics Inc.	BUY	$65.1M	NA	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$37.7B	57.21%	71.21	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$116.5B	140.42%	27.22	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$63.7B	13.39%	14.85	29.65%	0.58%

Stock Returns calculator for Acrivon Therapeutics Inc. Stock including INR - Dollar returns

The Acrivon Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Acrivon Therapeutics Inc. investment value today

Current value as on today

₹1,37,917

Returns

₹37,917

(+37.92%)

Returns from Acrivon Therapeutics Inc. Stock

₹26,613 (+26.61%)

Dollar Impact

₹11,304 (+11.3%)

Analyst Recommendation on Acrivon Therapeutics Inc. Stock

Based on 16 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 16 analysts, 87.5% of analysts recommend a 'BUY' rating for Acrivon Therapeutics Inc.. Average target price of $11.5

Acrivon Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Acrivon Therapeutics Inc..

What analysts predicted

86.35%UPSIDE

Target Price

$11.5

Current Price

$1.57

Analyzed by

16 Analysts

Target

$11.50

Acrivon Therapeutics Inc. target price $11.5, a slight upside of 86.35% compared to current price of $1.57. According to 16 analysts rating.

Indian Investors' Interest in Acrivon Therapeutics Inc. Stock

Search interest for Acrivon Therapeutics Inc. Stock has decreased by -2% in the last 30 days, reflecting a downward trend in search activity.

Time period: May 23, 2026 to June 22, 2026

Change:-2% versus previous 30 day period

Acrivon Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	1	-	-	-	0	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-21	-17	-21	-25	-24	-21	-22	-19	-20	-19
EBITDA	-19	-16	-18	-22	-22	-19	-20	-17	-24	-18
Interest Expense	1	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-19	-16	-18	-22	-22	-19	-21	-18	-18	-19
Income Tax Expense	1	0	-	-	0	-	-	-	-	-
Net Income	-19	-16	-18	-22	-22	-19	-21	-18	-18	-19
Net Profit Margin	-1021.87%	0.00%	0.00%	0.00%	-2692.33%	0.00%	0.00%	0.00%	0.00%	0.00%

Acrivon Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-
Gross Profit	0	0	-1	0	-1	-1
Operating Income	-3	-16	-32	-67	-89	-84
EBITDA	-5	-16	-32	-59	-79	-76
Interest Expense	-	0	1	-	-	-
Depreciation	0	0	0	0	1	1
Income Before Tax	-5	-16	-31	-60	-80	-77
Income Tax Expense	0	0	-1	0	-	-
Net Income	-5	-16	-29	-60	-80	-77
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Acrivon Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-16	-18	-22	-22	-19	-21	-18	-18	-19
Operating Cash Flow	-17	-13	-17	-17	-19	-16	-12	-15	-20
Investing Cash Flow	5	-88	16	14	19	19	5	21	13
Financing Cash Flow	0	123	-1	0	0	0	0	0	0
Change in Cash	-11	21	-2	-3	0	2	-6	6	-7

Acrivon Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-16	-31	-60	-80	-77
Operating Cash Flow	-13	-30	-42	-65	-63
Investing Cash Flow	0	-141	50	-51	66
Financing Cash Flow	112	101	-1	121	0
Change in Cash	98	-70	6	3	1

Global Institutional Holdings in Acrivon Therapeutics Inc.

Funds	Holdings
Geode Capital Management, LLC	0.55%
Sands Capital Ventures, LLC	4.96%
Marshall Wace Asset Management Ltd	1.31%
Two Sigma Advisers, LLC	0.78%
Bridgeway Capital Management, LLC	0.37%

See all

Insights on Acrivon Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, ACRV has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECT
Against Peers
In the last 3 years, Acrivon Therapeutics, Inc. Common Stock has experienced a drawdown of -88.2%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 66.5%
NEGATIVE IMPACT
Price Dip
In the last 3 years, ACRV stock has moved down by -88.2%

About Acrivon Therapeutics Inc.

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Organisation	Acrivon Therapeutics Inc.
Headquarters	480 Arsenal Way, Watertown, MA, United States, 02472
Industry	Biotechnology
CEO	Dr. Peter Blume-Jensen M.D., Ph.D.
E-voting on shares	Click here to vote

Key Management of Acrivon Therapeutics Inc.

Name	Title
Dr. Eric J. Devroe Ph.D.	Chief Operating Officer
Dr. Adam D. Levy M.B.A., Ph.D.	CFO & Principal Financial Officer
Ms. Katharine Peterson CPA	Vice President of Finance & Accounting
Ms. Mary-Alice Miller J.D.	Chief Legal Officer & Corporate Secretary
Dr. Jesper V. Olsen Ph.D.	Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board
Dr. Peter Blume-Jensen M.D., Ph.D.	Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
Ms. Kristina Masson M.B.A., Ph.D.	Co-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director
Mr. Bruce Close	Vice President of Quality & Compliance
Dr. Erick Gamelin M.D., Ph.D.	Chief Development Officer
Mr. Joon Jung Ph.D.	VP & Head of Data Science

FAQs

What is Acrivon Therapeutics Inc. share price today?

Acrivon Therapeutics Inc. share price today is $1.57 as on June 19, 2026 at 8:46 am IST at the close of the market. Acrivon Therapeutics Inc. share today touched a day high of $1.61 and a low of $1.51.

What is the 52 week high and 52 week low for Acrivon Therapeutics Inc. share?

Acrivon Therapeutics Inc. share touched a 52 week high of $3.56 on January 7, 2026 and a 52 week low of $1.15 on July 1, 2025. Acrivon Therapeutics Inc. stock price today i.e. June 19, 2026 at 8:46 am IST is closed at $1.57,which is 55.90% down from its 52 week high and 36.52% up from its 52 week low.

What is Acrivon Therapeutics Inc.'s market capitalisation today?

Acrivon Therapeutics Inc. market capitalisation is $0.00T as on June 19, 2026 at 8:46 am IST.

How to invest in Acrivon Therapeutics Inc. Stock (ACRV) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Acrivon Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Acrivon Therapeutics Inc. Shares that will get you 0.9554 shares as per Acrivon Therapeutics Inc. share price of $1.57 per share as on June 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Acrivon Therapeutics Inc. Stock (ACRV) from India?

Indian investors can start investing in Acrivon Therapeutics Inc. (ACRV) shares with as little as ₹94.31 or $1 (as of June 22, 2026 at 5:39 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Acrivon Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on June 22, 2026 at 5:39 am IST). Based on Acrivon Therapeutics Inc. share’s latest price of $1.57 as on June 19, 2026 at 8:46 am IST, you will get 6.3694 shares of Acrivon Therapeutics Inc.. Learn more about fractional shares .